Background. As access to antiretroviral therapy (ART) in Africa has increased dramatically, concerns have been raised regarding patient attrition, an important measure of program quality.
can meet increasing demands for treatment without compromising program quality. Prior studies of patient attrition, an important measure of program quality, have reported inconsistent results. Small studies from urban facilities, largely in South Africa and the early phase of treatment scale-up, and a more recent multicountry study reporting on private health facilities found increasing attrition over calendar time as HIV treatment programs expanded [6] [7] [8] [9] [10] , while a large government program in western Kenya showed improvements over time [11] . As these studies were limited in scope-focusing on small cohorts, private facilities, or limited geographic areas-data from more generalizable samples are needed.
Using aggregate data on 307 144 patients initiating ART at 638 PEPFAR-supported facilities in 9 SSA countries, our primary objective was to assess trends in 6-and 12-month attrition in a large, diverse HIV treatment program from 2005 to 2010. The 6-year evaluation period was characterized by unprecedented expansion of ART with 3.1 million patients initiated on ART through PEPFAR alone [12] .
METHODS

Design
We conducted a longitudinal ecological analysis utilizing data on successive cohorts of patients initiating ART at health facilities receiving support from ICAP at Columbia University via PEPFAR in Cote d'Ivoire, Ethiopia, Kenya, Lesotho, Mozambique, Nigeria, Rwanda, South Africa, and Tanzania.
Data Source
We used aggregate, facility-level data that were collected quarterly by ICAP staff for monitoring purposes on a standardized reporting form. These data were tallied by trained staff from paper-based registers or summarized from electronic patientlevel databases maintained by health facilities. The data included (1) the number of patients receiving ART and transferring out per quarter disaggregated by sex, and (2) CD4 count and attrition data for successive cohorts of patients initiating ART 6 and 12 months earlier. The latter were collected only for patients who were at least 6 years of age. Routine data quality assurance exercises assessed the completeness and consistency of reported data. Institutional review boards at Columbia University and the US Centers for Disease Control and Prevention, and in-country national ethical review committees provided nonresearch determination for this analysis as it utilized existing aggregate data.
Inclusion Criteria
We included health facilities if (1) they reported cohort data for at least 3 quarters between January 2005 and December 2010 and (2) information was available on the type and location of the health facility. To minimize the effects of data quality issues and very small cohort sizes when health facilities begin providing ART services, the first 2 cohort reports from each facility were excluded.
Outcomes and Independent Variables
Two outcomes were assessed: cohort attrition 6 months after ART initiation and cohort attrition 12 months after ART initiation. Cohort attrition was defined as the proportion of patients in each cohort who were no longer on ART at the health facility where they had initiated it. Patients who died, were lost to follow-up, or remained in care but stopped ART for any reason were considered no longer on ART. Following PEPFAR guidance, patients who transferred into a health facility after initiating ART were retrospectively added into the appropriate cohort at the receiving facility based on their ART initiation date, while patients who transferred out to another facility after initiating ART were excluded from the cohort at the initiating facility.
The main independent variables evaluated were calendar time and ART service maturity. Calendar time was operationalized as a quarter time count (ie, consecutive 4-month periods) and captured temporal trends in attrition. ART service maturity was defined as the number of quarters that a facility had been providing ART services to reflect facility experience that may accumulate over time and affect program quality. Additional facility-level characteristics that may also affect attrition were examined, including facility location (urban, semiurban, and rural) and type (primary, secondary/tertiary, private/other), ART patient load (number of patients currently on ART), the proportion of each cohort with complete CD4 count data at ART initiation, median CD4 count at ART initiation for each cohort, and the proportion of ART patients in a given quarter who were female and were documented to have transferred to another facility.
Statistical Analysis
We examined the magnitude and change in 6-and 12-month attrition over calendar time and ART service maturity by estimating and then averaging facility-specific trends. Poisson regression models were fit treating counts of attrition as the outcome with the number of patients in the cohort as the offset term. Generalized estimating equations accounting for repeated measures within facilities generated robust standard errors. As calendar time and ART service maturity were operationalized as continuous time measures, the models produced risk ratios for attrition per one quarter increase in calendar time or ART service maturity. We also constructed overall and country-specific multivariate models including the additional facility-level variables described above. Facility-level variables were treated as time-dependent covariates except for facility location and type. Continuous measures for which clinically relevant categories did not apply were categorized in tertiles to facilitate interpretation. We also controlled for country in overall models to account for unmeasured country-specific factors that may affect attrition (ie health systems, policy, economic, or cultural differences). Sensitivity analyses tested the robustness of the overall trends by excluding individual countries and examining the extent to which each country influenced the results, and given that the mix of countries and facilities supported by ICAP changed over time, assessed trends solely among the 8 facilities that contributed data for the entire 6-year evaluation period. Analyses were conducted using SAS version 9.3 software (SAS Institute, Cary, North Carolina).
RESULTS
Facility and ART Cohort Characteristics
Of 840 ICAP-supported health facilities providing ART services at any point between January 2005 and December 2010, 638 (80%) met the inclusion criteria. These 638 facilities reported data for 5638 successive 6-month cohorts with a total of 307 144 patients initiating ART, representing 88% of the 347 536 patients who started ART at the included facilities during the observation period. There were also 4937 twelve-month cohorts with a total of 272 677 patients newly initiating ART. Table 1 shows the evolution in facility and cohort characteristics. Table 1 ).
Overall Trends in Attrition
The average 6-and 12-month attrition across all cohorts and countries over the evaluation period was 21% and 29%, respectively (Table 2) . In unadjusted analyses, no significant change in 6-and 12-month attrition was observed over calendar time: 6-month attrition was 21% among 1722 patients in 17 health facilities who initiated ART in July 2005, and similarly was 21% among 19 378 patients in 470 facilities who initiated ART in December 2010 (P = .8735) ( Figure 1A ). Twelve-month attrition was 26% among 349 patients in 9 facilities in early 2005 and 29% among 20 335 patients in 432 facilities in late 2010 (P = .5717). Additionally, for the same period, attrition remained stable as ART services matured within health facilities ( Figure 1B ). Sixmonth attrition was 22% for cohorts initiating ART in the first year of ART service operations and 23% for cohorts initiating in the sixth year of operations (P = .3055). Twelve-month attrition followed a similar pattern (25% in year 1 vs 32% in year 6, P = .2277). Consistent results were obtained when individual countries were excluded from the analysis and when the analysis was restricted to facilities that contributed data for the entire observation period.
In adjusted analyses, neither calendar time nor ART service maturity was associated with 6-or 12-month attrition across the 9 countries. Table 3 shows additional facility-level variables associated with 6-and 12-month attrition in adjusted analyses. Cohorts that initiated ART in facilities with proportionally fewer women on ART (<54% vs 65%-100%), a higher proportion of patients reported to have transferred out (≥8% vs <3%), a lower proportion of patients with CD4 count documentation at ART initiation (<85% vs 100%), and lower median cohort CD4 count at ART initiation (<100 cells/µL vs ≥200 cells/µL) had higher 6-month attrition. Cohorts initiating ART in facilities in semiurban areas, with proportionally more documented transfers and proportionally fewer patients with CD4 count documentation at ART initiation had higher 12-month attrition. High ART patient volume (≥443 vs 1-135) was associated with lower 12-month attrition.
Country-Specific Trends in Attrition
The lowest average 6-and 12-month attrition, respectively, was observed in Rwanda at 9% and 15%, and the highest in Cote d'Ivoire at 39% and 46% (Table 2) . Unadjusted analyses showed decreasing 6-month attrition over calendar time in Ethiopia and Kenya, and stable attrition in 7 countries (Figure 2A ). Twelvemonth attrition significantly decreased in Ethiopia, increased in Cote d'Ivoire, Nigeria, and Rwanda, and remained stable in the remaining countries over calendar time ( Figure 2B ). Unadjusted analyses also showed variation in 6-month and 12-month attrition as ART services matured, but in most countries, attrition decreased or remained stable ( Figure 2C and 2D) . In country-specific adjusted models, no independent effect of calendar time on attrition was observed with one exception (Figure 2A and 2B): 12-month attrition increased over calendar time in Nigeria. Adjusted analyses also showed that increasing maturity of ART services was associated with decreasing 6-month attrition in Kenya and Lesotho, decreasing 12-month attrition in Lesotho and Nigeria, and increasing 6-and 12-month attrition in Mozambique (Figure 2C and 2D) .
DISCUSSION
We explored the association between rapid and massive scale-up of ART services and trends in 6-and 12-month attrition, an important measure of program quality, among 307 144 patients initiating ART at 638 health facilities in 9 SSA countries that represent substantial diversity in facility types and sizes, HIV prevalence, and health systems. From 2005 to 2010, there was a 10-fold increase in the number of supported facilities and a 5-fold increase in the number of patients initiating ART. Over the same period, services were decentralized toward smaller, primary health facilities and away from urban centers, and both median CD4 cell count at ART initiation and documentation of CD4 cell count at ART initiation increased. Despite the expansion and evolution in facility and cohort characteristics, No. of Countries (n = 9) (n = 6) (n = 8) (n = 8) (n = 9) (n = 9) (n = 8) attrition remained remarkably stable over time and as ART services matured across the 9 countries. This finding is encouraging, indicating that when examined from the perspective of multiple countries, there has been no deterioration in retention over time as has been reported in several smaller analyses and discussed in the policy discourse regarding the sustainability of ART programs [6] [7] [8] 13] . Further, while these program-wide trends may mask variability by country, 6-and 12-month attrition remained stable or decreased over calendar time and as ART services matured in the majority of countries examined, indicating that expanded access to HIV treatment need not translate into increased attrition. Overall attrition 6 and 12 months after ART initiation during the 6-year observation period was 21% and 29%, respectively. These proportions are comparable to those observed in prior reviews of ART attrition from SSA and in a review from resource-rich countries [14] [15] [16] [17] [18] . At the same time, further work is needed to decrease attrition, particularly as efforts to reach the latest global treatment targets are scaled up. Several facilityand cohort-level factors were associated with cohort attrition and point to areas for potential intervention or further research. Consistent with that of smaller studies using individual-level data [19, 20] , incomplete documentation of CD4 count at ART initiation was associated with increased attrition. While this may reflect poor quality of care, it is also possible that the observed association results from patients with advanced HIV disease initiating ART based solely on clinical staging. Cohorts initiating ART at facilities with a higher proportion of documented transfers also had higher 6-and 12-month attrition. This could suggest that as services are decentralized, facilities that are known to be transferring more patients also have a substantial number of undocumented transfers, resulting in misclassification of those patients as lost to follow-up. In contrast to prior studies [7, 8] , we found that higher patient volume was independently associated with decreased 12-month attrition. Smaller facilities may lack the resources available at larger facilities, including specialized staff members who provide supportive services to prevent attrition and track patients missing appointments in an effort to reengage them in care. Furthermore, cohorts that initiated ART in facilities with proportionally fewer women on ART were at increased risk of 6-month attrition, consistent with prior studies reporting sex differences in attrition [21] [22] [23] [24] . This may reflect men enrolling in care and initiating ART at more advanced stages of HIV [20, 24, 25] and thus being at increased risk for short-term mortality [26, 27] . Encouragingly no sex differences in attrition were observed at 12 months, suggesting high levels of adherence among men successfully retained beyond the first 6 months of treatment as reported previously [19, 28] . Lower median cohort CD4 count at ART initiation was also associated with increased 6-month attrition, consistent with other studies and likely reflecting higher death rates in patients with advanced HIV disease [9, 29] . This analysis has several important strengths. With data on >300 000 patients accounting for approximately 10% (range across countries, 4.2%-52.4%) of all persons initiated on ART through PEPFAR from 2005 to 2010 [12] and drawn from 638 HIV facilities representing a wide variety of facility types and sizes from 9 countries with heterogeneous epidemics and health systems, we believe it is the most comprehensive assessment of ART attrition to date. Six years of observation allowed examination of trends in attrition over a rapidly expanding phase of ART programmatic scale-up, and as national programs and patient populations changed significantly. Outcomes from this critical period in the global HIV response can inform renewed efforts to accelerate the initiation of patients on ART to meet the 2020 UNAIDS targets. We were also able to examine the effect of multiple important measures of scale-up on attrition over time. Additionally, use of routinely collected program data increased generalizability, allowing us to draw programmatically relevant conclusions. Several limitations should also be noted. Attrition was operationalized as the proportion of patients no longer receiving ART at their initiating health facility. However, undocumented transfers between facilities are common and may inflate estimates of attrition. Implementation of systems to better assess outcomes of patients not returning for care at a given facility will be critical to more fully describe patient outcomes. Indeed, attrition is a composite measure including patients who died, were lost to follow-up, and stopped ART, but trends over time and determinants of each of these outcomes may differ. Additionally, as we used aggregate-level cohort data, the effect and extent of unmeasured differences in patient populations on observed associations could not fully be examined. Last, while a large majority of ICAP-supported facilities were included in this analysis, excluded facilities were significantly less experienced and had fewer patients.
CONCLUSIONS
Our findings provide much-needed information regarding an important metric of program quality in the context of rapid scale-up of ART services, and suggest that improvements in program outcomes are possible even as ART coverage increases as will be needed in coming years. While we observed increasing attrition over time and as ART services matured in a small subset of countries examined, stable or decreasing attrition was noted in most. However, despite these encouraging findings, attrition levels observed in this large, multicountry HIV treatment program are insufficient to facilitate achievement of the UNAIDS targets. Implementation and evaluation of new models of service delivery that may further decrease attrition are urgently needed.
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